Based on the fact that NAFLD has a strong correlation with excess inflammation response and impaired cholesterol efflux capacity (CEC), we further elucidate the potential and efficacy of baicalin-induced mononuclear-cell (MNC)-derived MERTK+/hi M2c macrophages to be used as a cell-based therapy to treat NAFLD. This evidence concerns the gene MERTK and metabolic dysfunction-associated steatotic liver disease.